Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Novo Nordisk A/S (NVO) vs Pfizer Inc (PFE) Price & Performance

Novo Nordisk A/STrade
Pfizer IncTrade

Price performance (Past 24H)

Key statistics

Novo Nordisk A/S vs Pfizer Inc — how do they compare? Novo Nordisk A/S trades at $45.84 (market cap $207.85B), while Pfizer Inc trades at $26.4 (market cap $151.73B). The key difference: Novo Nordisk A/S is the larger of the two by market cap, and Pfizer Inc pays the higher dividend (6.46%). Which is the better fit depends on your goals.

NVOPFE
Market Cap
$207.85B$151.73B
Sector
HealthHealth
52-Week High
$63.98$28.56
52-Week Low
$35.29$23.60
Enterprise Value
$222.55B$203.22B
Dividend Yield
3.81%6.46%
Volume
29,869,932

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Novo Nordisk A/S

NVO trades at $47.73, up 0.99% today, with a neutral technical signal and strong fundamentals, including a P/E of 11.62 and net income margin of 35.35%. Recent Q2 2026 earnings beat expectations, but the stock faces mixed sentiment due to competitive pressures and pricing headwinds in its GLP-1 portfolio.

The outlook is cautiously optimistic, supported by robust profitability and analyst buy ratings (57.9%), but risks include intense competition from Eli Lilly and margin compression. Upside potential hinges on execution against guidance, while downside risks stem from market share erosion.

Pfizer Inc

Pfizer (PFE) trades at $27.05, up 1.16% with a bullish technical signal and consistent earnings beats in recent quarters. Revenue remains stable around $62-63 billion, though net income is projected to decline in 2026. The stock shows strong profitability margins and a solid balance sheet, but faces headwinds from patent expirations and competitive pressures.

The outlook is mixed: valuation multiples appear reasonable, and analyst consensus leans hold with a $27.86 target. Key risks include execution on pipeline catalysts and margin compression. Upside depends on successful drug launches and cost management amid a challenging revenue environment.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Novo Nordisk A/S

With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Read more on NVO

About Pfizer Inc

Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.

Read more on PFE